Blueprint Medicines Corp (NASDAQ:BPMC) insider Ariel Hurley sold 415 shares of the stock in a transaction on Monday, September 16th. The shares were sold at an average price of $78.14, for a total transaction of $32,428.10. Following the transaction, the insider now directly owns 415 shares in the company, valued at $32,428.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Ariel Hurley also recently made the following trade(s):

  • On Thursday, August 15th, Ariel Hurley sold 415 shares of Blueprint Medicines stock. The shares were sold at an average price of $84.02, for a total transaction of $34,868.30.
  • On Friday, July 19th, Ariel Hurley sold 115 shares of Blueprint Medicines stock. The shares were sold at an average price of $100.00, for a total transaction of $11,500.00.
  • On Monday, July 15th, Ariel Hurley sold 830 shares of Blueprint Medicines stock. The shares were sold at an average price of $94.98, for a total transaction of $78,833.40.

Blueprint Medicines stock traded up $0.73 during midday trading on Thursday, hitting $80.22. 7,338 shares of the stock were exchanged, compared to its average volume of 442,360. Blueprint Medicines Corp has a fifty-two week low of $44.58 and a fifty-two week high of $102.98. The stock has a market capitalization of $3.90 billion, a price-to-earnings ratio of -15.00 and a beta of 1.64. The stock’s 50-day simple moving average is $82.49 and its 200 day simple moving average is $84.78. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 0.16.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($2.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.92) by ($0.12). Blueprint Medicines had a negative net margin of 4,268.74% and a negative return on equity of 73.73%. The company had revenue of $5.11 million for the quarter, compared to analyst estimates of $1.39 million. During the same quarter in the prior year, the business earned ($0.62) earnings per share. Blueprint Medicines’s revenue was down 87.7% on a year-over-year basis. Equities analysts anticipate that Blueprint Medicines Corp will post -8.63 EPS for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the business. Strs Ohio increased its position in shares of Blueprint Medicines by 60.9% during the second quarter. Strs Ohio now owns 7,400 shares of the biotechnology company’s stock valued at $698,000 after acquiring an additional 2,800 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Blueprint Medicines by 40.6% in the first quarter. JPMorgan Chase & Co. now owns 111,374 shares of the biotechnology company’s stock valued at $8,915,000 after purchasing an additional 32,152 shares during the period. WCM Investment Management LLC purchased a new position in shares of Blueprint Medicines in the second quarter valued at approximately $518,000. Westfield Capital Management Co. LP boosted its stake in shares of Blueprint Medicines by 31.1% in the second quarter. Westfield Capital Management Co. LP now owns 612,380 shares of the biotechnology company’s stock valued at $57,766,000 after purchasing an additional 145,339 shares during the period. Finally, Axiom International Investors LLC DE boosted its stake in shares of Blueprint Medicines by 25.5% in the second quarter. Axiom International Investors LLC DE now owns 20,327 shares of the biotechnology company’s stock valued at $1,917,000 after purchasing an additional 4,130 shares during the period. Institutional investors and hedge funds own 99.29% of the company’s stock.

Several research firms have issued reports on BPMC. Piper Jaffray Companies reaffirmed a “hold” rating on shares of Blueprint Medicines in a report on Monday, September 9th. Zacks Investment Research cut shares of Blueprint Medicines from a “buy” rating to a “sell” rating and set a $94.00 target price for the company. in a research report on Wednesday, August 7th. Cowen reiterated a “buy” rating on shares of Blueprint Medicines in a research report on Monday, September 9th. Canaccord Genuity increased their target price on shares of Blueprint Medicines from $105.00 to $120.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Finally, BidaskClub cut shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research report on Thursday, August 22nd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $108.22.

About Blueprint Medicines

Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

Featured Article: What is Put Option Volume?

Insider Buying and Selling by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.